Positron emission tomography in patients with Hodgkin's disease:: Correlation to histopathologic subtypes

被引:16
作者
Döbert, N
Menzel, C
Berner, U
Hamscho, N
Wördehoff, N
Mitrou, P
Grünwald, F
机构
[1] Univ Hosp Frankfurt, Dept Nucl Med, D-60590 Frankfurt, Germany
[2] Univ Hosp Frankfurt, Dept Internal Med, D-60590 Frankfurt, Germany
关键词
Hodgkin's disease; positron emission tomography (PET); histopathologic subtypes;
D O I
10.1089/108497803322287646
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The aim of this study was to evaluate the initial staging and restaging of Hodgkin's disease (HD) according to histopathologic subtype (HST) using fluorine-18-deoxyglucose-positron emission tomography (PET). Special attention was paid to the accuracy of PET for detection of bone marrow infiltration (BMI). 44 patients with HD (m:f = 28:16, mean age 36 +/- 15 years) underwent PET; 16 were primary stagings and 28 restaging examinations. PET results were compared with methods of conventional staging including computed tomography (CT) and bone marrow biopsy. Viable tumor tissue was detected by PET in 25/44 cases, 16 nodular sclerosis (NS), 4 mixed cellularity (MC), 3 lymphocyte predominance (LP) and 2 cases with a nonclassified subtype (NC). FDG tumor uptake, measured as standard uptake value (SUV), ranged from 1.7 to 13. Maximum SUV in NS was 5.2 +/- 1.5 (2.5-7.3), 3.2 +/- 2.4 for MC, 2.6 +/- 0.7 for LP, and 9.1 +/- 3.8 for NC, respectively. In 7% of all patients (3/44) bone marrow infiltrations were detected by PET. PET is known for its superior detection of viable tissue in HD. In this study it was shown that HST does not influence the intensity of glucose metabolism, although 2 patients with NC showed the highest SUVs. In addition PET accurately detected focal BMI and may thus be applied before BMB to guide its optimal use.
引用
收藏
页码:565 / 571
页数:7
相关论文
共 18 条
[1]
Buchmann I, 2000, RECENT RESULTS CANC, V156, P78
[2]
RESIDUAL MASS IN LYMPHOMA MAY NOT BE RESIDUAL DISEASE [J].
CANELLOS, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (06) :931-933
[3]
Detection of lymphoma in bone marrow by whole-body positron emission tomography [J].
Carr, R ;
Barrington, SF ;
Madan, B ;
O'Doherty, MJ ;
Saunders, CAB ;
van der Walt, J ;
Timothy, AR .
BLOOD, 1998, 91 (09) :3340-3346
[4]
Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma [J].
Cremerius, U ;
Fabry, U ;
Neuerburg, J ;
Zimny, M ;
Osieka, R ;
Buell, U .
NUCLEAR MEDICINE COMMUNICATIONS, 1998, 19 (11) :1055-1063
[5]
DIEHL M, 2002, NUKLEARMEDIZIN, V73
[6]
BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group [J].
Diehl, V ;
Franklin, J ;
Hasenclever, D ;
Tesch, H ;
Pfreundschuh, M ;
Lathan, B ;
Paulus, U ;
Sieber, M ;
Rueffer, JU ;
Sextro, M ;
Engert, A ;
Wolf, J ;
Hermann, R ;
Holmer, L ;
Stappert-Jahn, U ;
Winnerlein-Trump, E ;
Wulf, G ;
Krause, S ;
Glunz, A ;
von Kalle, K ;
Bischoff, H ;
Haedicke, C ;
Duehmke, E ;
Georgii, A ;
Loeffler, M .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) :3810-3821
[7]
ISRAEL O, 1988, CANCER, V61, P2439, DOI 10.1002/1097-0142(19880615)61:12<2439::AID-CNCR2820611208>3.0.CO
[8]
2-Q
[9]
Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging [J].
Jerusalem, G ;
Beguin, Y ;
Fassotte, MF ;
Najjar, F ;
Paulus, P ;
Rigo, P ;
Fillet, G .
BLOOD, 1999, 94 (02) :429-433
[10]
Jerusalem G, 2001, HAEMATOLOGICA, V86, P266